Skip to main content

Table 2 Patient and treatment characteristics of the case group and control group

From: Dosimetric predictors of temporal lobe injury after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma: a competing risk study

Variable

Case group

Control group

P value

Median age (y)

49

48

ND

Age range (y)

27–72

28–70

ND

Male

56 (88.9)

56 (88.9)

ND

Female

7 (11.1)

7 (11.1)

ND

N-classification

0.069

 N0–1

31 (49.2)

41 (65.1)

 N2–3

32 (50.8)

22 (34.9)

AJCC 2010 stage

0.752

 IVA

58 (92.1)

57 (90.5)

 IVB

5 (7.9)

6 (9.5)

Chemotherapy

 Induction

60 (95.2)

56 (88.9)

0.187

 Concurrent

36 (57.1)

42 (66.7)

0.271

 Adjuvant

20 (31.7)

19 (30.2)

1.000

Concurrent cetuximab or nimotuzumab

7 (11.1)

3 (4.8)

0.187

Nasopharynx boost

4 (6.3)

1 (1.6)

0.365a

Overall treatment time (OTT)

0.859

 ≤ 45

25 (39.7)

19 (30.1)

 > 45

38 (60.3)

44 (69.8)

Temporal lobe Dmax (Gy)

75.22 (63.83–80.16)

72.64 (61.35–79.35)

< 0.001

Temporal lobe D1cc (Gy)

72.52 (54.47–77.21)

66.81 (54.40–74.95)

< 0.001

Temporal lobe V20 (cc)

48.18 (21.26–75.20)

38.06 (15.01–79.18)

< 0.001

Temporal lobe V30 (cc)

31.64 (10.22–56.35)

23.94 (8.55–55.09)

< 0.001

Temporal lobe V40 (cc)

20.11 (6.09–43.16)

15.09 (5.63–37.47)

< 0.001

Temporal lobe V50 (cc)

13.23 (2.76–31.28)

8.84 (2.23–29.56)

< 0.001

Temporal lobe V60 (cc)

7.59 (0.2–19.71)

3.65 (0.24–19.45)

< 0.001

Temporal lobe V70 (cc)

2, 26 (0–9.18)

0.26 (0–8.22)

< 0.001

  1. Abbreviation: AJCC American Joint Committee on Cancer, ND not done;
  2. aP value with Fisher Exact Test
  3. Values are number (percentage) or median (range)